Get the Stockscreener App
2.325
3.93%
-0.095
After Hours:
2.34
0.015
+0.65%
Cytomx Therapeutics Inc stock is traded at $2.325, with a volume of 5.22M.
It is down -3.93% in the last 24 hours and down -29.33% over the past month.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
See More
Previous Close:
$2.42
Open:
$2.45
24h Volume:
5.22M
Relative Volume:
1.66
Market Cap:
$506.62M
Revenue:
$35.54M
Net Income/Loss:
$-59.14M
P/E Ratio:
-6.3926
EPS:
-0.3637
Net Cash Flow:
$-80.19M
1W Performance:
-9.18%
1M Performance:
-29.33%
6M Performance:
-47.04%
1Y Performance:
-31.62%
1-Day Range:
$2.32
$2.45
1-Week Range:
$2.32
$2.65
52-Week Range:
$2.32
$8.21
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
Name
Cytomx Therapeutics Inc
Sector
Industry
Phone
650.515.3185
Address
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Compare CTMX vs VRTX, MRNA, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTMX
Cytomx Therapeutics Inc
|
2.325 | 506.62M | 35.54M | -59.14M | -80.19M | -0.3637 |
VRTX
Vertex Pharmaceuticals Inc
|
485.22 | 122.98B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
216.25 | 86.33B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
753.12 | 77.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
802.64 | 50.47B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.44 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-19-26 | Initiated | Wolfe Research | Outperform |
| Mar-16-26 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-20-26 | Initiated | Guggenheim | Buy |
| Sep-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-17-25 | Resumed | Barclays | Overweight |
| Jul-31-25 | Initiated | Oppenheimer | Outperform |
| May-15-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-14-25 | Resumed | Piper Sandler | Overweight |
| May-28-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| May-09-24 | Upgrade | Wedbush | Neutral → Outperform |
| May-06-24 | Upgrade | Jefferies | Hold → Buy |
| Apr-22-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Nov-14-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jul-07-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-07-22 | Downgrade | Mizuho | Buy → Neutral |
| Jul-07-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-22 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
| Jan-18-22 | Upgrade | Barclays | Underweight → Overweight |
| Nov-15-21 | Initiated | BTIG Research | Buy |
| May-28-21 | Downgrade | Barclays | Equal Weight → Underweight |
| Mar-29-21 | Initiated | JP Morgan | Overweight |
| Mar-23-21 | Upgrade | Jefferies | Hold → Buy |
| Sep-22-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-01-20 | Downgrade | Jefferies | Buy → Hold |
| May-14-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-24-20 | Upgrade | Wedbush | Neutral → Outperform |
| Mar-04-20 | Initiated | Barclays | Equal Weight |
| Nov-20-19 | Initiated | Guggenheim | Buy |
| Nov-11-19 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-13-19 | Initiated | Mizuho | Buy |
| May-14-19 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-11-19 | Initiated | Barclays | Overweight |
| Nov-26-18 | Initiated | Piper Jaffray | Overweight |
| Oct-15-18 | Initiated | Goldman | Neutral |
| Sep-13-18 | Initiated | H.C. Wainwright | Buy |
| Jun-01-18 | Initiated | SunTrust | Buy |
| Jan-05-18 | Initiated | Citigroup | Buy |
| Sep-08-17 | Initiated | Wedbush | Outperform |
| Mar-27-17 | Initiated | H.C. Wainwright | Buy |
| Mar-02-17 | Initiated | Instinet | Buy |
| Jan-03-17 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-02-15 | Initiated | Oppenheimer | Outperform |
View All
Cytomx Therapeutics Inc Stock (CTMX) Latest News
CytomX outlines cancer strategy. CytomX Therapeutics stock trades ahead of November 5 results - AD HOC NEWS
Cytomx Therapeutics Stock Price Forecast. Should You Buy CTMX? - StockInvest.us
Cytomx Thera (CTMX-Q) Stock Price and News - The Globe and Mail
CytomX Therapeutics (CTMX) Short Interest & Short Float | Updated Sep 2026 - marketbeat.com
CytomX Therapeutics (NasdaqGS:CTMX) Stock Forecast & Analyst Predictions - Simply Wall Street
CytomX Therapeutics Inc (6C1) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
CytomX Therapeutics, Inc. (CTMX) Presents at Wells Fargo 21st Annual Healthcare ConferenceSlideshow (NASDAQ:CTMX) 2026-09-10 - Seeking Alpha
CytomX at cantor healthcare conference: pipeline gains, safety test ahead By Investing.com - Investing.com South Africa
CytomX at cantor healthcare conference: pipeline gains, safety test ahead By Investing.com - Investing.com Australia
CytomX at cantor healthcare conference: pipeline gains, safety test ahead By Investing.com - Investing.com Nigeria
CytomX at cantor healthcare conference: pipeline gains, safety test ahead - investing.com
CytomX at cantor healthcare conference: pipeline gains, safety test ahead By Investing.com - Investing.com India
CytomX at Wells Fargo conference: epcam bet and cash strength - investing.com
CTMXCytomX Therapeutics Inc Revenue Breakdown - Finviz
CytomX Therapeutics to Present at Upcoming September Investor Conferences - Stock Titan
CytomX Therapeutics to Present at Upcoming September Investor Conferences - finance.yahoo.com
FDA grants fast track status to CytomX’s colorectal cancer drug By Investing.com - Investing.com Canada
FDA grants fast track status to CytomX’s colorectal cancer drug - Investing.com India
FDA grants fast track status to CytomX’s colorectal cancer drug - Investing.com
FDA grants fast track status to CytomX’s colorectal cancer drug By Investing.com - Investing.com UK
CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC) - finance.yahoo.com
CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan ('Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC) - The Manila Times
FDA Fast Track status comes as CytomX plans a 2027 colorectal cancer study - Stock Titan
CytomX (CTMX) Stock: Ends Up by 1.37% at $3.33 for the Current Session; the Price Remains Bounded by the Supplied Support and Resistance in the Current UpdateVanna Flow - siam.in
CytomX (CTMX) Stock: Ends Up by 1.37% at $3.33 for the Current Session; the Price Remains Bounded by the Supplied Support and Resistance in the Current UpdateProfit Surge Picks - vinanet.vn
CytomX Therapeutics (NASDAQ:CTMX) Downgraded to "Hold" Rating by Zacks Research - MarketBeat
CytomX Therapeutics (CTMX) Climbs 2.68% to $3.45, Trades Within Key Support-Resistance RangeHidden Order - vinanet.vn
CytomX Therapeutics (NASDAQ:CTMX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Point72’s 3.6% CytomX Therapeutics (CTMX) stake detailed in amended filing - Stock Titan
Kynam Capital reports 9.96% CytomX Therapeutics (CTMX) ownership in Schedule 13G/A - Stock Titan
CytomX Therapeutics, Inc.: Target Price Consensus and Analysts Recommendations | CTMX | US23284F1057 - marketscreener.com
CTMX Maintained by JP Morgan -- Price Target Lowered to $11.00 - GuruFocus
CytomX Therapeutics (NASDAQ:CTMX) Given New $11.00 Price Target at JPMorgan Chase & Co. - MarketBeat
CytomX Therapeutics Is Maintained at Overweight by JP Morgan - Moomoo
Bank of America Corp DE Has $47.95 Million Position in CytomX Therapeutics, Inc. $CTMX - marketbeat.com
MSN Money - MSN
CytomX Therapeutics: Promising Varseta-M With Comfortable Runway (NASDAQ:CTMX) - Seeking Alpha
CytomX upgrades to speculative Buy on promising cancer drug Varseta-M and expanded Regeneron partnership - Pluang
CTMX Maintained by Guggenheim -- Price Target Lowered to $14.00 - GuruFocus
Guggenheim cuts CytomX stock price target to $14 on model update - Investing.com South Africa
Guggenheim cuts CytomX stock price target to $14 on model update - Investing.com Australia
Guggenheim cuts CytomX stock price target to $14 on model update - Investing.com Nigeria
Guggenheim cuts CytomX stock price target to $14 on model update - Investing.com
Guggenheim cuts CytomX stock price target to $14 on model update - Investing.com Canada
Guggenheim cuts CytomX stock price target to $14 on model update - Investing.com India
Guggenheim cuts CytomX stock price target to $14 on model update - Investing.com UK
CytomX Therapeutics, Inc. $CTMX Shares Purchased by Dimensional Fund Advisors LP - MarketBeat
Q2 2026 CytomX Therapeutics Inc Earnings Call Transcript - GuruFocus
Q4 2025 CytomX Therapeutics Inc Earnings Call Transcript - GuruFocus
Analysts Offer Insights on Healthcare Companies: CytomX Therapeutics (CTMX), Cytokinetics (CYTK) and Scholar Rock Holding (SRRK) - The Globe and Mail
Cytomx Therapeutics Inc Stock (CTMX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cytomx Therapeutics Inc Stock (CTMX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Chu Yu-Waye | Chief Medical Officer |
Mar 17 '26 |
Sale |
6.42 |
21,279 |
136,675 |
189,446 |
| McCarthy Sean A. | CEO |
Mar 17 '26 |
Sale |
6.42 |
118,969 |
764,138 |
1,078,922 |
| BELVIN MARCIA | SVP, Chief Scientific Officer |
Mar 17 '26 |
Sale |
6.42 |
31,492 |
202,273 |
300,760 |
| Ogden Christopher | Chief Financial Officer |
Mar 17 '26 |
Sale |
6.42 |
19,323 |
124,112 |
296,948 |
| McCarthy Sean A. | CEO |
Nov 06 '25 |
Sale |
4.54 |
101,793 |
461,906 |
987,891 |
| Sean McCarthy | CEO |
Nov 06 '25 |
Proposed Sale |
4.54 |
101,793 |
461,909 |
0 |
4.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):